RMED VS ATXI Stock Comparison

Performance

RMED
10/100

RMED returned -95.79% in the last 12 months. Based on SPY's performance of -8.73%, its performance is below average giving it a score of 10 of 100.

ATXI
10/100

ATXI returned -87.93% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

Analyst Price Targets

RMED
75/100

4 analysts offer 12-month price targets for RMED. Together, they have an average target of 0, the most optimistic target put RMED at 0 within 12-months and the most pessimistic has RMED at 0. These analyst ratings are from our partners at Financial Modeling Prep and Alpha Vantage.

ATXI
88/100

2 analysts offer 12-month price targets for ATXI. Together, they have an average target of 0, the most optimistic target put ATXI at 0 within 12-months and the most pessimistic has ATXI at 0.

Technicals

RMED
11/100

RMED receives a 10 of 100 based on 14 indicators. 1 are bullish, 12 are bearish.

ATXI
14/100

ATXI receives a 14 of 100 based on 14 indicators. 2 are bullish, 12 are bearish.

Earnings

RMED
10/100

RMED has missed earnings 12 times in the last 20 quarters.

ATXI
10/100

ATXI has missed earnings 4 times in the last 20 quarters.

Profit

RMED
10/100

Out of the last 20 quarters, RMED has had 0 profitable quarters and has increased their profits year over year on 0 of them.

ATXI
10/100

Out of the last 20 quarters, ATXI has had 1 profitable quarters and has increased their profits year over year on 1 of them.

Volatility

RMED
44/100

RMED has had a lower than average amount of volatility over the last 12 months giving it a score of 44 of 100.

ATXI
48/100

ATXI has had a lower than average amount of volatility over the last 12 months giving it a score of 47 of 100.

All score calculations are broken down here to help you make more informed investing decisions

Ra Medical Systems, Inc Summary

Healthcare

Medical Devices

Ra Medical Systems, Inc., a medical device company, develops, manufactures, and markets excimer lasers for use in the treatment of vascular immune-mediated inflammatory diseases. It offers destruction of arteriosclerotic blockages by laser radiation ablation, a minimally invasive excimer laser and single-use catheter system that is used by physicians in the endovascular treatment of vascular blockages resulting from lower extremity vascular disease. The company sells its products primarily through distributors in the United States. Ra Medical Systems, Inc. was incorporated in 2002 and is headquartered in Carlsbad, California.

Avenue Therapeutics, Inc. Common Stock Summary

Nasdaq / ATXI

Healthcare

Biotechnology

Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, a synthetic dual-acting opioid, which is in Phase III clinical trials for the treatment of post-operative acute pain. The company was incorporated in 2015 and is based in New York, New York.

Power up your portfolio